Market revenue in 2023 | USD 364.6 million |
Market revenue in 2030 | USD 440.1 million |
Growth rate | 2.7% (CAGR from 2023 to 2030) |
Largest segment | Biosimilars |
Fastest growing segment | Biosimilars |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Biologics, Biosimilars |
Key market players worldwide | Johnson & Johnson, Novartis AG ADR, Teva Pharmaceutical Industries Ltd, Amgen Inc, Roche Holding AG ADR, Intapp Inc, Dr Reddy's Laboratories Ltd ADR, LG Chem, Sun Pharmaceutical Industries, Biocon |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to erythropoietin drugs market will help companies and investors design strategic landscapes.
Biosimilars was the largest segment with a revenue share of 57.13% in 2023. Horizon Databook has segmented the Latin America erythropoietin drugs market based on biologics, biosimilars covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America erythropoietin drugs market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America erythropoietin drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account